What to know about clinical flow cytometry

It is often used when clinicians need to characterise blood-forming or immune cells. The result supports diagnosis, classification, treatment planning, or follow-up, but it is interpreted alongside the sample appearance, blood results, symptoms, imaging, and sometimes genetic or molecular tests.

A laboratory prepares cells from blood, bone marrow, a lymph node, or another fluid or tissue. The cells are mixed with labelled antibodies that attach to selected markers, then pass individually through a laser-based instrument. Patterns of light and fluorescence help the laboratory distinguish cell groups and identify an unusual population.

A report may describe the sample quality, cell populations, marker pattern, and an interpretation. Terms such as positive or negative usually refer to whether a cell marker was detected; by themselves, they do not mean that the overall test proves or excludes cancer.

Preparation depends mainly on how the sample is collected. A routine blood sample may need little preparation, while a bone marrow or tissue procedure comes with separate instructions about medicines, eating, transport, and wound care. Confirm whether blood-thinning medicines or allergies need discussion; do not change medication without clinical advice.

Arrange a review of the complete report rather than trying to interpret a marker list alone. Ask what other tests are being combined with flow cytometry and whether the sample was adequate to answer the clinical question.

Flow cytometry itself is performed in a laboratory, so physical aftercare relates to the sample collection. After a marrow or tissue procedure, seek prompt advice for persistent bleeding, increasing redness or swelling, fever, worsening pain, or fluid from the collection site.

Get urgent help for breathing difficulty, fainting, severe bleeding, or a rapidly worsening reaction after a collection procedure. Use the discharge number provided by the clinic when available.

Consider asking which sample is needed, what diagnosis the test is assessing, when the integrated interpretation will be ready, and whether more sampling could be required. If monitoring an existing condition, ask what change in the cell population would alter the treatment plan.